Skip to main content
SHIFT Newsroom
Read the latest published stories →Medicine news and evidence →

GLP-1: Safe clinician led access for UK men, including oral tablets

Published 5 October 2026 · SHIFT Team

Decorative GLP-1 clinical access title card

Several GLP-1 medicines are now licensed for weight loss in the UK: semaglutide (injectable and oral), tirzepatide and as of August 2026, orforglipron (Foundayo). All of them are prescription-only. NHS access remains limited, so most people currently use private pathways, and the safest route is a regulated, clinician-led service that keeps your GP informed and monitors you throughout.

TL;DR:

- Most users in the UK access GLP-1 medicines privately due to NHS restrictions and long waiting lists, requiring proper clinical assessment and GP communication.
- Real-world weight loss typically reaches around 14% after a year with structured support, lower than trial figures but still clinically significant.
- Persisting with treatment and pacing dose increases are key factors for sustained weight loss, rather than maximum dosing alone.
- Stopping medication does not necessarily lead to weight regain if healthy habits are developed during treatment, though relapse risks vary.
- Choosing a clinical, regulated service with proper assessment, monitoring, and follow-up is essential to ensure safety and effective outcomes.

Table of Contents

1. Which GLP-1 medicines are authorised in the UK and how they work

As of June to August 2026, the UK has authorised several GLP-1 medicines for weight management: semaglutide in both injectable and oral form, tirzepatide, and orforglipron, sold as Foundayo. All are licensed for adults with a BMI of 30 or above, or 27 to 30 with a weight-related health condition, and every one of them is prescription-only.

These medicines work by mimicking a gut hormone that signals fullness to your brain, which tends to reduce appetite and slow how quickly your stomach empties. That's the shared mechanism. Where they differ is formulation. Injectable versions are usually once-weekly jabs, while oral semaglutide (Rybelsus) and the newer orforglipron tablet are taken daily. Tablets suit people who want to avoid injections, though daily dosing means daily discipline, and some tablets need to be taken on an empty stomach for proper absorption.

If you want the official detail rather than marketing copy, start here:

2. How prescribing and access work: NHS versus private routes

NHS access to GLP-1 medicines is tightly controlled by local commissioning decisions and NICE guidance, which means eligibility varies by area and waiting lists can be long even when you meet the clinical criteria. That gap is why most people currently accessing these medicines in the UK do so through private prescriptions rather than their GP surgery.

That doesn't mean private access is a free-for-all. GLP-1 medicines are prescription-only medicines, and the General Pharmaceutical Council is explicit that safe supply requires independent verification of BMI, a proper clinical history check, and screening for eating disorder risk before anyone is prescribed. Advertising and supply of these medicines sit under MHRA and GPhC oversight, not general consumer protection rules.

Before you commit to any private provider, check for:

  1. A genuine clinical assessment, not just a tick-box questionnaire
  2. Live video or in-person BMI verification, rather than a self-reported number
  3. A clear plan for how your GP will be notified
  4. A defined follow-up schedule, not a single transaction

Pro Tip: Ask any provider directly whether they notify your GP and whether a named clinician reviews your case, not just an algorithm.

Red flags include a service offering to ship medication without any assessment, no mention of GP communication, or pressure to buy a long course upfront before you've even had a consultation. For a fuller breakdown of how the two systems compare, see our NHS versus private weight-loss medication guide.

3. Benefits and risks: what the trials show and what can go wrong

Clinical trials give a sense of ceiling effects rather than what most people experience. In trial settings, semaglutide produced average weight loss of around 15%, while tirzepatide trials reported closer to 21%, though real-world cohorts tend to land lower than these figures once you account for dose titration pauses, tolerability issues and life simply getting in the way.

3. Benefits and risks: what the trials show and what can go wrong — overview diagram

A real-world cohort study found persistent users reached a median weight loss of around 14% at 12 months when supported by structured, multidisciplinary care, which is a meaningful gap below trial ceilings but still a substantial result. Some evidence also points to cardiovascular and kidney benefits in specific patient groups, though these findings don't automatically generalise to everyone on the medication, and they shouldn't be read as a reason to start treatment for reasons unrelated to weight.

Side effects are common enough that you should expect them, not be alarmed by them:

Rare but serious risks include pancreatitis and gallbladder problems, and persistent severe abdominal pain or jaundice warrants urgent medical attention rather than a wait-and-see approach.

4. Real-world outcomes: persistence, titration and what happens after stopping

Trial results are a ceiling. What actually happens depends heavily on whether you stick with treatment and how your dose is managed along the way. Structured clinical programmes that support people through the first six to twelve months tend to see outcomes closer to trial figures, largely because persistence, not maximum dose, is the stronger predictor of sustained loss.

That last point matters more than it sounds. Plenty of people assume they need to reach the highest licensed dose to see results, but moderate, well-tolerated titration paired with consistent use often outperforms a rushed escalation that triggers side effects and early drop-out.

Stopping treatment is the part people worry about most, and the evidence here is genuinely mixed rather than uniformly discouraging:

For practical detail on managing the transition off medication, our guide to stopping GLP-1 treatment covers relapse prevention and what aftercare should look like. And if you're specifically worried about losing muscle alongside fat, our piece on preventing GLP-1 muscle loss is worth a read before you start.

5. How to choose a safe, clinically governed service

Picking a provider matters as much as picking a drug. A legitimate service should offer a proper clinical assessment, verify your BMI by live video or in person rather than trusting a typed-in number, and set out clear rules for both titration and stopping before you ever take a dose.

Before signing up anywhere, ask:

  1. Who actually prescribes, and are they a UK-registered clinician?
  2. Which regulated pharmacy dispenses the medication?
  3. How are side effects monitored and managed if they occur?
  4. How long does follow-up last, and what happens after the prescription ends?
  5. What wraparound support, diet, movement, mental health, is included rather than bolted on?

Pro Tip: A provider that can't clearly explain its GP notification process in one sentence probably doesn't have one.

Watch for services offering to ship medication with no assessment at all, no mention of informing your GP, or an almost total absence of monitoring once you've paid. GPhC inspection reports on online pharmacies have repeatedly flagged exactly these gaps as the difference between safe and risky supply.

6. SHIFT Some Timber's approach: clinical pathways built around men

We built our programme around the gap between getting a prescription and actually changing your life. Clinical assessment, prescribing and dispensing run through appropriately regulated partners, with BMI and history checked properly before anyone starts. Alongside that sits The Programme: Grub for food that fits a normal week, Fit for movement that doesn't require a gym habit you don't have, Life Back for goals beyond the scales, and My Timber for tracking progress honestly.

We pay particular attention to preserving muscle during treatment, since appetite suppression without the right support can cost you strength as well as fat. Our own practice-level figures around oral semaglutide outcomes, including a 13.6% result we discuss in more detail in our oral semaglutide explainer, reflect what we see when medication is paired with structured support rather than left to run alone.

If you're considering an assessment, the useful preparation is simple: know your current weight and BMI, any existing health conditions, and what you've tried before.

7. What the research actually tells us about getting this right

The conventional advice on GLP-1 medicines treats the drug as the whole story: get prescribed, take the dose, watch the number drop. The evidence doesn't support that framing. Persistence and structured support predict outcomes more reliably than which exact molecule you're on, and the gap between trial results and real-world results is mostly explained by people stopping too early or escalating doses faster than their body tolerates.

The part that gets underweighted is what happens after you stop. Plenty of men assume stopping means automatic regain, which isn't what the data shows, but it also isn't automatic maintenance either. The difference seems to come down to whether you built habits around food and movement while the medication was doing the heavy lifting, or whether you just waited for the appetite suppression to do the work for you.

If you're starting this year, prioritise the clinical governance first: proper verification, GP communication, a stopping plan. Then prioritise the behavioural side just as seriously as the prescription itself.

— Matt O’Brien

If you want help now: how we support assessments and supervised pathways

We offer a regulated, clinician-led route into GLP-1 treatment for men who want the prescribing done properly and the support that comes after it taken seriously. Assessment and dispensing run through appropriately regulated partners, and the surrounding programme is designed to support progress beyond just the prescription.

Shift Some Timber Ltd

If you're not sure whether NHS or private access makes more sense for your situation, our comparison on NICE eligibility versus NHS access lays out why so many eligible men end up going private anyway. When you're ready, book an assessment and we'll talk you through what fits.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

FAQ

Which GLP-1 is best for weight loss in the UK?

There's no single "best" medicine; tirzepatide has shown higher average weight loss than semaglutide in trials, but tolerability, cost and your own health history matter more than chasing the biggest headline number. A clinician should help you weigh that against your specific case rather than picking based on trial averages alone.

Can you get GLP-1 pills in the UK?

Yes, oral semaglutide (Rybelsus) and the newer orforglipron tablet (Foundayo) are both licensed in the UK as prescription-only medicines. You still need a proper clinical assessment before either can be prescribed.

How to lose 2 stone in 12 weeks on the NHS?

The NHS doesn't promise a fixed timeline or amount of weight loss, and losing that much in 12 weeks would be unusually fast for most structured programmes. GLP-1 medicines paired with dietary and activity support can produce substantial loss over months, but pace and safety matter more than hitting a specific number by a specific date.

How much do GLP-1 pills cost in the UK?

Costs vary by provider, medicine and dose, and we don't publish a single figure here because pricing depends on your specific treatment plan. Ask any provider for a clear breakdown before committing, including what's covered in ongoing follow-up.

How does GLP-1 aid weight loss?

GLP-1 medicines mimic a gut hormone that signals fullness, which tends to reduce appetite and slow stomach emptying. That generally leads to eating less without constant hunger, though the effect varies between individuals and tends to work best alongside dietary and lifestyle changes.

Sources